ReviewTherapeutics and clinical risk management2026
A Multi-Disciplinary Approach to the Management of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer.
Review in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy is a cornerstone of comprehensive breast cancer treatment. However, its non-specific cytotoxic effects frequently involve the gastrointestinal tract, leading to a spectrum of digestive adverse reactions, including chemotherapy-induced nausea and vomiting (CINV), anorexia, diarrhea, and constipation. These symptoms not only compromise patients' quality of life but may also impair treatment adherence. In severe cases, they can necessitate dose reduction or treatment discontinuation. This review systematically examines the epidemiology, pathophysiology, and classification of gastrointestinal adverse reactions associated with breast cancer chemotherapy, with a focus on CINV management strategies. These strategies include pharmacological prophylaxis, individualized risk assessment, non-pharmacological interventions, and the use of standardized assessment tools. Based on the available evidence, we discuss the transition from an experience-based nursing model to a predictive one. We also emphasize the importance of patient education, psychological support, and family involvement, and highlight specific considerations for breast cancer patients. This review provides a systematic, evidence‑based reference for the clinical care of CINV in breast cancer to optimize gastrointestinal symptom management and improve treatment outcomes and quality of life for these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.